Real World Data on Gi(l)Otrif® Dose Adjustment

Boehringer Ingelheim228 enrolled

Overview

This is a non-interventional, multi-country, multi-site study based on existing data from medical records of patients treated with Gi(l)otrif® as part of the routine treatment according to the approved label. Data from real-world will help to understand if dose modifications are done similar as in LUX-Lung 3 trial and if the outcome on safety and effectiveness are as in trial settings. Furthermore, data on modified starting doses, the underlying reasons and effects on safety and outcome are needed.

Study Type

OBSERVATIONAL

Enrollment

228

Conditions

Carcinoma, Non-Small-Cell Lung

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion criteria: 1. Age = 18 years 2. Patients with Epidermal growth factor receptor (EGFR) mutation (common mutations), tyrosine kinase inhibitors (TKI)-naïve advanced non small cell lung cancer (NSCLC), treated with Gi(l)otrif® as the first-line treatment for NSCLC within the approved label 3. Signed and dated written informed consent per regulations. (Exemption of a written informed consent for retrospective observational studies in some countries per local regulations and legal requirements.) Exclusion criteria: 1. Any contraindication to Gi(l)otrif® as specified in label. 2. Patients with uncommon mutations are excluded as uncommon mutations are not within label in all participating countries (e.g. USA). 3. Patients still on treatment with Gi(l)otrif® will be excluded unless treatment period is \> or = 6 months. 4. Patients treated with Gi(l)otrif® within an interventional trial.

Locations (29)

Outcomes

Primary Outcomes

Percentage of Patients With Adverse Drug Reactions (ADR) by Severity Class.

An adverse drug reaction (ADR) is defined as a response to a medicinal product which is noxious and unintended. Grade 1, Grade 2, Grade 3 and Grade 4 ADR severity classes were considered for assessment of this outcome.

Time frame: From signing the informed consent onwards until the end of the study, up to 104 weeks.

Time on Treatment With Gi(l)Otrif®

Time on treatment with Gi(l)otrif® in real-world setting has been calculated in this assessment. Time on treatment refers to time to treatment failure with Gi(l)otrif®

Time frame: From first dose of Gi(l)otrif® treatment to last dose of Gi(l)otrif® treatment, up to 104 weeks.

Time to Progression With Gi(l)Otrif®

Time to progression was calculated from the date of first dose of Gi(l)otrif® treatment to the earliest date of documented progression (clinical, radiographic or both clinical/radiographic progression) or tumour-related death, whatever occurred first.

Time frame: From first dose of Gi(l)otrif® treatment to last dose of Gi(l)otrif® treatment, up to 104 weeks.

Secondary Outcomes

Percentage of Patients With a Modified Starting Dose of Gi(l)Otrif®

Percentage of patients with a modified starting dose that is dose other than the recommended 40 mg daily of Gi(l)otrif® has been calculated to assess this outcome measure.

Time frame: From first dose of Gi(l)otrif® treatment to last dose of Gi(l)otrif® treatment, up to 104 weeks.

Percentage of Patients With Reasons for Modified Starting Dose of Gi(l)Otrif®

Different reasons for starting dose with modified dose that is dose other than recommended 40 mg once daily.

Time frame: From first dose of Gi(l)otrif® treatment to last dose of Gi(l)otrif® treatment, up to 104 weeks.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.